ReviewDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2026
Poly (lactic-co-glycolic acid) nanoplatforms for triple-negative breast cancer: current progress, advances, and future outlook.
Review in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is a highly aggressive subtype with the poorest prognosis and the highest recurrence rates. PLGA nanoplatforms show great potential as delivery systems for treating aggressive TNBC. A wide variety of nanoplatforms have been developed and evaluated for potential use in TNBC imaging and treatment. Poly (lactic-co-glycolic acid) (PLGA) is a biodegradable and biocompatible polymer used in the design of various types of nanoplatforms. PLGA is FDA approved and enables the encapsulation of multiple anticancer agents for targeted, sustained release. By incorporating various functional elements into PLGA or PLGA nanoplatforms, enhanced tumour targeting and diagnostic capabilities can be achieved. The interior space or surface of PLGA can be used to adsorb hydrophobic or hydrophilic drug molecules. This review examines recent developments in the design of PLGA nanoformulations that mimic biological barriers to enhance the therapeutic effectiveness of anticancer drugs against TNBC. Structural engineering significantly affects drug delivery capabilities. The current review provides insights into the pathophysiological pathways of TNBC, encompassing the pharmacokinetic challenges of current treatment strategies. The primary focus of this review is to collate and discuss novel PLGA based drug delivery strategies, the biocompatibility of PLGA, the significance of combination therapies, clinical relevance, and FDA approval. We also present the mechanisms underlying multidrug resistance and systemic toxicity, and discuss how smart responsive systems can be used to overcome these barriers. In addition, we emphasize the challenges posed by regulatory guidelines for TNBC and PLGA, as well as scale-up and reproducibility issues. The PLGA based drug delivery approaches are also reviewed in the context of recent preclinical and clinical studies. Future research and development in this domain may focus on critical aspects such as AI guided design and multifunctional systems, integration with precision medicine and personalized therapy, and combination with immunotherapy to enhance the efficacy and safety of PLGA based delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.